Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
$4.83+10.27%
报价 2026-11-06
市值
$992.4M
EV
$980.7M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -30.4%
$4.00$6.94
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| SVRASavara Inc. | $992.4M | +10.3% | +307.1% | 0% | – | – | – | |
| TNGXTango Therapeutics, Inc. | $3.63B | +3.0% | -90.3% | 98.3% | – | – | – | |
| NBTXNanobiotix S.A. | $1.56B | +2.0% | – | 100% | – | – | – | |
| GHRSGH Research PLC | $1.28B | +0.9% | – | 0% | – | – | – | |
| TYRATyra Biosciences, Inc. | $1.26B | +1.2% | – | 0% | – | – | – | |
| KURAKura Oncology, Inc. | $646.7M | +6.9% | +11.1% | 94.7% | – | – | – | |
| GERNGeron Corporation | $635.9M | +4.2% | +25.5% | 66.7% | – | – | – | |
| BCAXBicara Therapeutics Inc. Common Stock | $572.4M | +5.6% | – | 0% | – | – | – | |
| PROKProKidney Corp. | $383.3M | +7.0% | -40.0% | -252.6% | – | – | – | |
| 同行中位数 | – | – | -14.4% | 33.4% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。